Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial

Sci Rep. 2015 May 19;5:10344. doi: 10.1038/srep10344.


Our previous studies have shown that mangiferin decreased serum triglycerides and free fatty acids (FFAs) by increasing FFAs oxidation in both animal and cell experiments. This study sought to evaluate the effects of mangiferin on serum lipid profiles in overweight patients with hyperlipidemia. Overweight patients with hyperlipidemia (serum triglyceride ≥ 1.70 mmol/L, and total cholesterol ≥ 5.2 mmol/L) were included in this double-blind randomized controlled trial. Participants were randomly allocated to groups, either receiving mangiferin (150 mg/day) or identical placebo for 12 weeks. The lipid profile and serum levels of mangiferin, glucose, L-carnitine, β-hydroxybutyrate, and acetoacetate were determined at baseline and 12 weeks. A total of 97 participants completed the trial. Compared with the placebo control, mangiferin supplementation significantly decreased the serum levels of triglycerides and FFAs, and insulin resistance index. Mangiferin supplementation also significantly increased the serum levels of mangiferin, high-density lipoprotein cholesterol, L-carnitine, β-hydroxybutyrate, and acetoacetate, and increased lipoprotein lipase activity. However, there were no differences in the serum levels of total cholesterol, low-density lipoprotein cholesterol, serum glucose, and insulin between groups. Mangiferin supplementation could improve serum lipid profiles by reducing serum triglycerides and FFAs in overweight patients with hyperlipidemia, partly due to the promotion of FFAs oxidation.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Hydroxybutyric Acid / blood
  • Acetoacetates / blood
  • Blood Glucose / drug effects
  • Carnitine / blood
  • Cholesterol, HDL / blood
  • Dietary Supplements
  • Double-Blind Method
  • Fatty Acids, Nonesterified / blood
  • Female
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy*
  • Insulin Resistance / physiology*
  • Lipids / blood*
  • Lipoprotein Lipase / metabolism
  • Male
  • Middle Aged
  • Overweight / blood*
  • Placebos
  • Xanthones / therapeutic use*


  • Acetoacetates
  • Blood Glucose
  • Cholesterol, HDL
  • Fatty Acids, Nonesterified
  • Lipids
  • Placebos
  • Xanthones
  • mangiferin
  • acetoacetic acid
  • Lipoprotein Lipase
  • Carnitine
  • 3-Hydroxybutyric Acid